BRPI0908175A2 - derivados de polimixina e composição farmacêuticas contendo os derivados de polimixina seus usos e métodos de preparação - Google Patents

derivados de polimixina e composição farmacêuticas contendo os derivados de polimixina seus usos e métodos de preparação

Info

Publication number
BRPI0908175A2
BRPI0908175A2 BRPI0908175A BRPI0908175A BRPI0908175A2 BR PI0908175 A2 BRPI0908175 A2 BR PI0908175A2 BR PI0908175 A BRPI0908175 A BR PI0908175A BR PI0908175 A BRPI0908175 A BR PI0908175A BR PI0908175 A2 BRPI0908175 A2 BR PI0908175A2
Authority
BR
Brazil
Prior art keywords
polymyxin derivatives
preparation
methods
pharmaceutical composition
composition containing
Prior art date
Application number
BRPI0908175A
Other languages
English (en)
Inventor
Martti Vaara
Timo Vaara
Original Assignee
Northern Antibiotics Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20085110A external-priority patent/FI20085110A0/fi
Application filed by Northern Antibiotics Oy filed Critical Northern Antibiotics Oy
Publication of BRPI0908175A2 publication Critical patent/BRPI0908175A2/pt
Publication of BRPI0908175B1 publication Critical patent/BRPI0908175B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0908175-5A 2008-02-08 2009-02-05 Derivados de polimixina e composições farmacêuticas contendo os derivados de polimixina seus usos e métodos de preparação BRPI0908175B1 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US6521408P 2008-02-08 2008-02-08
FI20085110 2008-02-08
US61/065,214 2008-02-08
FI20085110A FI20085110A0 (fi) 2008-02-08 2008-02-08 Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
US12793308P 2008-05-16 2008-05-16
FI20085469A FI20085469A0 (fi) 2008-02-08 2008-05-16 Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
FI20085469 2008-05-16
US61/127,933 2008-05-16
PCT/FI2009/050093 WO2009098357A1 (en) 2008-02-08 2009-02-05 Short fatty acid tail polymyxin derivatives and uses thereof

Publications (2)

Publication Number Publication Date
BRPI0908175A2 true BRPI0908175A2 (pt) 2016-07-05
BRPI0908175B1 BRPI0908175B1 (pt) 2021-06-01

Family

ID=39523122

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908175-5A BRPI0908175B1 (pt) 2008-02-08 2009-02-05 Derivados de polimixina e composições farmacêuticas contendo os derivados de polimixina seus usos e métodos de preparação

Country Status (24)

Country Link
EP (2) EP2242765B1 (pt)
JP (2) JP5752421B2 (pt)
KR (1) KR101627139B1 (pt)
CN (2) CN101970461B (pt)
AU (1) AU2009211287B2 (pt)
BR (1) BRPI0908175B1 (pt)
CA (2) CA2713467C (pt)
CY (1) CY1118625T1 (pt)
DK (1) DK2242765T3 (pt)
ES (1) ES2615813T3 (pt)
FI (1) FI20085469A0 (pt)
HR (1) HRP20170108T1 (pt)
HU (1) HUE031095T2 (pt)
IL (2) IL207275A (pt)
LT (1) LT2242765T (pt)
MX (1) MX2010008674A (pt)
NZ (1) NZ587131A (pt)
PL (1) PL2242765T3 (pt)
PT (1) PT2242765T (pt)
RU (1) RU2492179C2 (pt)
SI (1) SI2242765T1 (pt)
TW (1) TWI383801B (pt)
WO (1) WO2009098357A1 (pt)
ZA (1) ZA201005668B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20085469A0 (fi) * 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
BR112014012016A2 (pt) * 2011-11-18 2017-05-16 Cantab Anti-Infectives Ltd compostos
CN102863518B (zh) * 2012-10-09 2014-04-30 湖北美林药业有限公司 一种多粘菌素b化合物及其制备方法
JP6643758B2 (ja) 2013-05-22 2020-02-12 スペロ・セラピューティクス・インコーポレーテッド 異なった抗生物質と一緒の組合せ療法におけるポリミキシン誘導体及びその使用
FR3016888B1 (fr) * 2014-01-27 2021-01-22 Centre Nat Rech Scient Synthetases de la colistine et cluster de genes correspondants
CN107108699A (zh) 2014-11-26 2017-08-29 新药物许可控股有限公司 化合物
US9771394B2 (en) * 2014-12-16 2017-09-26 Micurx Pharmaceuticals, Inc. Antimicrobial polymyxins for treatment of bacterial infections
FI126143B (en) * 2015-01-15 2016-07-15 Northern Antibiotics Oy Polymyxine derivative and its uses
CN109512998A (zh) * 2016-03-04 2019-03-26 广州英赛特生物技术有限公司 含氧碳氢衍生物的酯化衍生物作为多粘菌素的协同增效剂的应用
WO2017189866A1 (en) * 2016-04-27 2017-11-02 Spero Opco Polymyxin analogs useful as antibiotic potentiators
JP2019515007A (ja) * 2016-05-13 2019-06-06 スペロ ポテンシエーター インコーポレイテッドＳｐｅｒｏ Ｐｏｔｅｎｔｉａｔｏｒ， Ｉｎｃ． 新規カチオン性ペプチドｓｐｒ７４１による、抗生物質活性の増強
JP2019519497A (ja) * 2016-05-13 2019-07-11 スペロ ポテンシエーター インコーポレイテッドＳｐｅｒｏ Ｐｏｔｅｎｔｉａｔｏｒ， Ｉｎｃ． Ｓｐｒ７４１のヒト薬物動態及び有効用量
WO2019085926A1 (zh) * 2017-10-31 2019-05-09 上海医药工业研究院 多黏菌素类似物及其制备方法
AU2018359018B2 (en) * 2017-11-02 2022-11-24 The University Of Queensland Peptide antibiotics
MD3810633T2 (ro) 2018-06-25 2024-05-31 Spero Therapeutics Inc Compuşi
CN110179967A (zh) * 2019-05-28 2019-08-30 中国医药集团总公司四川抗菌素工业研究所 多粘菌素母核和一种抗生素的组合物及其应用
US20220265766A1 (en) * 2019-07-30 2022-08-25 The Regents Of The University Of California Antimicrobial therapy through the combination of pore-forming agents and histones
IT201900025414A1 (it) 2019-12-23 2021-06-23 Univ Bologna Alma Mater Studiorum Composto per il trattamento della sindrome emolitico uremica
CN111072757B (zh) * 2020-01-02 2021-10-15 上海上药第一生化药业有限公司 多黏菌素b组分或其盐及其制备方法和应用
JP7045520B2 (ja) 2020-01-02 2022-03-31 上海上薬第一生化薬業有限公司 ポリミキシンｂ成分又はその塩、その製造方法及び使用
EP4125994A4 (en) * 2020-03-25 2024-06-12 Aufbau Medical Innovations Limited METHODS AND MEDICAL TREATMENTS FOR GLAUCOMA
US20220395555A1 (en) * 2020-06-11 2022-12-15 Boris Farber Derivatives of antibiotics
CN118201946A (zh) * 2021-08-12 2024-06-14 奥克兰联合服务有限公司 脂化多粘菌素类似物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3450687A (en) 1966-02-24 1969-06-17 Pfizer & Co C Lower alkanoyl esters of polymyxin antibiotics
JPS4915537B1 (pt) 1970-03-25 1974-04-16
US4485039A (en) * 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
US5620955A (en) * 1993-06-18 1997-04-15 Peptide Technologies Corporation Bombesin receptor antagonists and uses thereof
WO2002055543A2 (en) 2001-01-16 2002-07-18 Univ Ramot Hybrid peptides for treatment of bacteremia and septicemia
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
HUE028271T2 (en) * 2006-08-11 2016-12-28 Northern Antibiotics Oy Polymixin derivatives and their applications
FI20085469A0 (fi) * 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä

Also Published As

Publication number Publication date
WO2009098357A1 (en) 2009-08-13
HUE031095T2 (en) 2017-06-28
RU2010135809A (ru) 2012-03-20
FI20085469A0 (fi) 2008-05-16
AU2009211287A1 (en) 2009-08-13
PL2242765T3 (pl) 2017-07-31
JP6050854B2 (ja) 2016-12-21
IL233430A0 (en) 2014-08-31
TWI383801B (zh) 2013-02-01
HRP20170108T1 (hr) 2017-06-02
CN104086633B (zh) 2018-02-09
CA2979273C (en) 2020-03-24
ZA201005668B (en) 2014-01-29
KR20100130984A (ko) 2010-12-14
EP2242765A1 (en) 2010-10-27
MX2010008674A (es) 2010-10-04
CN101970461B (zh) 2015-04-08
EP3263586A1 (en) 2018-01-03
CA2713467A1 (en) 2009-08-13
SI2242765T1 (sl) 2017-04-26
TW200936153A (en) 2009-09-01
AU2009211287B2 (en) 2013-08-15
KR101627139B1 (ko) 2016-06-07
DK2242765T3 (en) 2017-02-27
CY1118625T1 (el) 2017-07-12
EP2242765B1 (en) 2017-01-11
CN104086633A (zh) 2014-10-08
LT2242765T (lt) 2017-02-10
NZ587131A (en) 2013-01-25
BRPI0908175B1 (pt) 2021-06-01
PT2242765T (pt) 2017-02-16
CA2979273A1 (en) 2009-08-13
JP2015145399A (ja) 2015-08-13
RU2492179C2 (ru) 2013-09-10
JP2011511045A (ja) 2011-04-07
IL207275A (en) 2015-07-30
JP5752421B2 (ja) 2015-07-22
CA2713467C (en) 2017-11-21
ES2615813T3 (es) 2017-06-08
IL207275A0 (en) 2010-12-30
CN101970461A (zh) 2011-02-09

Similar Documents

Publication Publication Date Title
BRPI0908175A2 (pt) derivados de polimixina e composição farmacêuticas contendo os derivados de polimixina seus usos e métodos de preparação
HRP20161312T1 (hr) Postupak za pripravu farmaceutske formulacije kontrastnih sredstava
IL294095A (en) Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
BRPI1011876A2 (pt) "composição farmacêutica estável e métodos de uso da mesma"
IL241985A0 (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
EP2139596A4 (en) PREPARATION OF POLYSACCHARID BEADS
BRPI1012333A2 (pt) atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
BRPI1011830A2 (pt) microencapsulação de substância bioativas e métodos de preparação da mesma
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
IL252119B (en) Improved cell composition and methods of making the same
BRPI0819971A2 (pt) anticorpos contra vírus influenza e métodos de seu uso
BRPI1008878A2 (pt) compostos heterocíclicos, composições farmacêuticas contendo os mesmos, e seus usos como inibidores de transportador de glicina 1
BRPI0913726A2 (pt) rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos
PT2473527T (pt) Formulações estáveis de polipéptidos e seus usos
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
BRPI0907628A2 (pt) Derivados bicíclicos de carboxamidas azabicíclicas, preparação dos mesmos e uso terapêutico dos mesmos
PL2413912T3 (pl) Preparaty farmaceutyczne zawierające pochodne nitrokatecholu oraz metody ich wytwarzania
BRPI0913640A2 (pt) substâncias policrômicas e seus usos
BRPI0907077A2 (pt) métodos e composições para administração oral de proteínas
CR10665A (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
BR112013022556A8 (pt) composição farmacêutica aquosa semissólida contendo tapentadol, seu uso e uso de tapentadol
BRPI0913441A2 (pt) Composição prebiótica e métodos de produção e uso da mesma
BR112012028524A2 (pt) composições farmacêuticas, respectivos usos e métodos de preparação, composição sólida solúvel em água e kits
BR112013013179A2 (pt) polimorfos de nor-udca ou bis-nor-udca, seu uso e método de preparação, bem como composições farmacêuticas que os compreendem
BR112013033472A2 (pt) derivado de camptotecina e método de preparação do mesmo e composição farmacêutica e aplicação

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/02/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2812 DE 26-11-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.